These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 23456439)

  • 1. Follistatin as potential therapeutic target in prostate cancer.
    Sepporta MV; Tumminello FM; Flandina C; Crescimanno M; Giammanco M; La Guardia M; di Majo D; Leto G
    Target Oncol; 2013 Dec; 8(4):215-23. PubMed ID: 23456439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The emerging role of follistatin under stresses and its implications in diseases.
    Zhang L; Liu K; Han B; Xu Z; Gao X
    Gene; 2018 Jan; 639():111-116. PubMed ID: 29020616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of ovarian function by the TGF-beta superfamily and follistatin.
    Lin SY; Morrison JR; Phillips DJ; de Kretser DM
    Reproduction; 2003 Aug; 126(2):133-48. PubMed ID: 12887271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activins and activin antagonists in the prostate and prostate cancer.
    Gold E; Risbridger G
    Mol Cell Endocrinol; 2012 Aug; 359(1-2):107-12. PubMed ID: 21787836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression and localization of activin subunits and follistatins in tissues from men with high grade prostate cancer.
    Thomas TZ; Wang H; Niclasen P; O'Bryan MK; Evans LW; Groome NP; Pedersen J; Risbridger GP
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3851-8. PubMed ID: 9360551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variations in activin receptor, inhibin/activin subunit and follistatin mRNAs in human prostate tumour tissues.
    van Schaik RH; Wierikx CD; Timmerman MA; Oomen MH; van Weerden WM; van der Kwast TH; van Steenbrugge GJ; de Jong FH
    Br J Cancer; 2000 Jan; 82(1):112-7. PubMed ID: 10638976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regional localization of activin-β
    Gold E; Zellhuber-McMillan S; Risbridger G; Marino FE
    Gene Expr Patterns; 2017 Jan; 23-24():70-79. PubMed ID: 28363632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and Therapeutic Implications of Follistatin in Solid Tumours.
    Shi L; Resaul J; Owen S; Ye L; Jiang WG
    Cancer Genomics Proteomics; 2016 11-12; 13(6):425-435. PubMed ID: 27807065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of activin A in oral squamous cell carcinoma: association with poor prognosis and tumor progression.
    Chang KP; Kao HK; Liang Y; Cheng MH; Chang YL; Liu SC; Lin YC; Ko TY; Lee YS; Tsai CL; Wang TH; Hao SP; Tsai CN
    Ann Surg Oncol; 2010 Jul; 17(7):1945-56. PubMed ID: 20309641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activin inhibition of prostate cancer cell growth: selective actions on androgen-responsive LNCaP cells.
    Dalkin AC; Gilrain JT; Bradshaw D; Myers CE
    Endocrinology; 1996 Dec; 137(12):5230-5. PubMed ID: 8940339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Follistatin is a metastasis suppressor in a mouse model of HER2-positive breast cancer.
    Seachrist DD; Sizemore ST; Johnson E; Abdul-Karim FW; Weber Bonk KL; Keri RA
    Breast Cancer Res; 2017 Jun; 19(1):66. PubMed ID: 28583174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of an activin-follistatin growth modulatory system in the human prostate: secretion and biological activity in primary cultures of prostatic epithelial cells.
    Wang Q; Tabatabaei S; Planz B; Lin CW; Sluss PM
    J Urol; 1999 Apr; 161(4):1378-84. PubMed ID: 10081911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The contribution of inhibins and activins to malignant prostate disease.
    Risbridger GP; Mellor SL; McPherson SJ; Schmitt JF
    Mol Cell Endocrinol; 2001 Jun; 180(1-2):149-53. PubMed ID: 11451585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The activins and their binding protein, follistatin-Diagnostic and therapeutic targets in inflammatory disease and fibrosis.
    Hedger MP; de Kretser DM
    Cytokine Growth Factor Rev; 2013 Jun; 24(3):285-95. PubMed ID: 23541927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activins in reproductive biology and beyond.
    Wijayarathna R; de Kretser DM
    Hum Reprod Update; 2016 Apr; 22(3):342-57. PubMed ID: 26884470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibins, activins, and follistatins: expression of mRNAs and cellular localization in tissues from men with benign prostatic hyperplasia.
    Thomas TZ; Chapman SM; Hong W; Gurusingfhe C; Mellor SL; Fletcher R; Pedersen J; Risbridger GP
    Prostate; 1998 Jan; 34(1):34-43. PubMed ID: 9428386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attenuation of bleomycin-induced pulmonary fibrosis by follistatin.
    Aoki F; Kurabayashi M; Hasegawa Y; Kojima I
    Am J Respir Crit Care Med; 2005 Sep; 172(6):713-20. PubMed ID: 15976370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Follistatin-related protein and follistatin differentially neutralize endogenous vs. exogenous activin.
    Sidis Y; Tortoriello DV; Holmes WE; Pan Y; Keutmann HT; Schneyer AL
    Endocrinology; 2002 May; 143(5):1613-24. PubMed ID: 11956142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential binding and neutralization of activins A and B by follistatin and follistatin like-3 (FSTL-3/FSRP/FLRG).
    Schneyer A; Schoen A; Quigg A; Sidis Y
    Endocrinology; 2003 May; 144(5):1671-4. PubMed ID: 12697670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imbalance between activin A and follistatin drives postburn hypertrophic scar formation in human skin.
    Fumagalli M; Musso T; Vermi W; Scutera S; Daniele R; Alotto D; Cambieri I; Ostorero A; Gentili F; Caposio P; Zucca M; Sozzani S; Stella M; Castagnoli C
    Exp Dermatol; 2007 Jul; 16(7):600-10. PubMed ID: 17576240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.